Immersive 3D vs Physical Simulation in Training Novices for Laser-Based Endourological Procedures: Protocol for a Randomized Controlled Trial.

JMIR Res ProtocOct 6, 2026 (epub)
Clinical ResearchUrology

Joséphine-Charlotte Coleman, Matthias J Witti, Natalia Wirtz et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial aims to compare immersive 3D simulation and physical simulation training for novice medical students in endourological laser-based procedures. The study will assess the impact of pretraining on immersive 3D simulation on technical skills transfer, cognitive load, motivation, and perceived learning outcomes. Results are expected by April 2027.

Key findings

  • The study will involve 70 medical students in a single-center trial.
  • Technical performance will be evaluated using an objective structured assessment and a critical error checklist.
  • Cognitive load, motivation, and perceived learning will also be measured alongside technical skills.

Why it matters

Understanding the effectiveness of different simulation modalities in medical training can enhance educational strategies, potentially improving procedural skills and outcomes for novice trainees in urology.

Source

PubMed · PMID 42837675

Published in JMIR Res Protoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.